Euro70 Million Investment in Generics
Stryków - Swiss Novartis AG will invest Euro70 million in a new generics production and logistics facility in Stryków, Poland. Operated by Slovenian generics leader Lek, a new Sandoz subsidiary, the new facility is expected to create 150 jobs in the Lódz region. The 25,000 m2 complex will include an administration building, laboratories, production lines and storage centres. “Today, we build on our 100 year presence in Poland with the opening of a major new facility. This better positions our generics business to participate in the exciting growth opportunities promised by the expansion of the European single market,” said Paul Choffat, CEO of Novartis Consumer Health.
Initially focused on the production of oral solid formulations of generic medicines including Ketonal, Amlopin, Lovastatinum and Altacet the plant is expected to reach a production capacity of 1.5 billion tablets and capsules in the first year. Export production is estimated at 10% in the first year of operation, rising to as much as 20% thereafter.